CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
CRISPR Therapeutics's price to sales ratio was 330.2× on Nov 11, 2026, against 83.2× a year earlier. Over the last 5 years it ranged from 4.2× to 411.3×, with a median of 29.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 330.2× | +201.8 |
| 2025 | Dec 31, 2025 | 128.4× | +111.8 |
| 2024 | Dec 31, 2024 | 16.6× | −12.7 |
| 2023 | Dec 29, 2023 | 29.2× | −196.5 |
| 2022 | Dec 30, 2022 | 225.7× | +219.3 |
| 2021 | Dec 31, 2021 | 6.4× | −133.3 |
| 2020 | Dec 31, 2020 | 139.7× | +123.9 |
| 2019 | Dec 31, 2019 | 15.8× | −25.9 |
| 2018 | Dec 31, 2018 | 41.7× | −44.4 |
| 2017 | Dec 29, 2017 | 86.1× | +51.0 |
| 2016 | Dec 30, 2016 | 35.1× | – |
See a number that looks wrong?